NovaBridge Biosciences (NBP) Construction in Progress (2021 - 2022)
NovaBridge Biosciences (NBP) posted quarterly Construction in Progress of $874276.2 for Q4 2022, down 73.51% year-on-year from $3.3 million in Q4 2021, and down 4.24% on a QoQ basis from $913000.0 in Q2 2022.
NovaBridge Biosciences (NBP) Construction in Progress (2021 - 2022) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Construction in Progress for 2 consecutive years, with $874276.2 the latest figure, recorded in Q4 2022.
- Quarterly Construction in Progress fell 73.51% year-over-year to $874276.2 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $874276.2 (down 73.51% YoY) and the FY2022 annual result came in at $901000.0, down 72.7% from the prior year.
- Construction in Progress fell to $874276.2 in Q4 2022 per NBP's latest filing, from $913000.0 in the prior quarter.
- Over the last five years, Construction in Progress for NBP reached as high as $139.9 million in Q2 2021 and fell as low as $874276.2 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 137.45 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | NovaBridge Biosciences | 389.86 Mn | 389.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 874,276.16 |
| Jun 30, 2022 | 913,000.00 |
| Dec 31, 2021 | 3.30 Mn |
| Jun 30, 2021 | 139.90 Mn |